STING-Activating Polymeric Nanovaccines for T Cell Therapy of Melanoma
用于黑色素瘤 T 细胞治疗的 STING 激活聚合物纳米疫苗
基本信息
- 批准号:9754799
- 负责人:
- 金额:$ 51.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-30 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:AnimalsAntigensCancer CenterCell physiologyClinicalClinical DataCombined Modality TherapyCytotoxic T-LymphocytesDendritic CellsDoseGoalsGuidelinesHistologyHuman PapillomavirusImmuneImmune checkpoint inhibitorImmune systemImmunocompetentIndividualInterferon ActivationInterferon Type ILarge Intestine CarcinomaLifeMC38Malignant NeoplasmsModelingMusMutateNanotechnologyNatureOrganPathway interactionsPatientsPeptidesPharmacology StudyPhasePolymersProductionProteinsProtocols documentationRefractoryResearch PersonnelSafetyT cell responseT cell therapyT-LymphocyteTestingTherapeuticTissuesToxic effectTumor AntigensTumor ImmunityVaccine AdjuvantVaccinesanti-CTLA4anti-PD-1armcancer carecancer immunotherapycancer therapycheckpoint inhibitioncheckpoint therapychemotherapyclinical translationcytokineimmunogenicimmunotoxicityinhibitor/antagonistlymph nodesmelanomamembernanoparticlenanovaccineneoantigensneoplasm immunotherapynovelpre-clinicalpreclinical evaluationprogramsresponsespatiotemporalsuccesssynergismsystemic toxicitytumortumor microenvironment
项目摘要
Abstract
Cancer immunotherapy is emerging as a new paradigm for the treatment of cancer by targeting
the body's immune system instead of tumor. Clinical approvals of several check point inhibitors (e.g.,
Ipilimumab, Pembrolizumab) have shown durable response in a small subset of melanoma patients
over conventional chemotherapy. Despite these successes, many cancers are poorly immunogenic
and do not generate adequate cytotoxic T lymphocytes (CTLs) and therefore these patients cannot
benefit from immune checkpoint therapies. The long-term goal of this application is to establish
STING-activating polymeric nanovaccines for cytotoxic T cell therapy of melanoma. We will capitalize
on the discovery of an ultra-pH sensitive polymer (PC7A) that allows optimal spatio-temporal
orchestration of cytosolic delivery of tumor antigen (Ag) in dendritic cells and innate stimulation for the
robust production of tumor-specific CTLs. A simple physical mixture of Ag-PC7A NP resulted in a
robust Th1 and CTL (>80%) response without the need of innate stimulants (i.e., CpG, Poly(I:C)). Use
of tumor associated antigens (TAAs) have shown significantly increased antitumor efficacy in a
B16F10 melanoma model in mice. We will test the central hypothesis that PC7A nanoparticle vaccine
will synergize with checkpoint inhibition to allow a safe and efficacious T cell therapy of melanoma.
There are three specific aims: (1) Expand the nanovaccine platform to multiple melanoma peptide
antigens; (2) Evaluate the safety of the polymeric nanovaccines in healthy, immunocompetent
animals; and (3) Evaluate the antitumor efficacy of the polymer nanovaccines and its synergy with
checkpoint inhibition. Accomplishments of the above aims will provide critical data for clinical
translation of the nanovaccines for melanoma therapy. We will also collaborate with other
nanoalliance members to test the PC7A NP in additional cancer indications.
摘要
癌症免疫治疗正在成为通过靶向治疗癌症的新范式
而不是肿瘤。几种检查点抑制剂的临床批准(例如,
Ipilimumab,Pembrolizumab)在一小部分黑色素瘤患者中显示出持久的反应
而不是传统的化疗。尽管取得了这些成功,但许多癌症的免疫原性很差
并且不能产生足够的细胞毒性T淋巴细胞(CTL),
从免疫检查点疗法中获益。本申请的长期目标是建立
STING激活聚合物纳米疫苗用于黑色素瘤的细胞毒性T细胞治疗。我们将利用
发现了一种超pH敏感聚合物(PC 7A),
树突状细胞中肿瘤抗原(Ag)的胞质递送的协调和对肿瘤细胞的先天刺激
肿瘤特异性CTL的稳健产生。Ag-PC 7A NP的简单物理混合物产生了
稳健的Th 1和CTL(>80%)应答而不需要先天刺激物(即,CpG,Poly(I:C))。使用
的肿瘤相关抗原(TAA)已显示出显着增加的抗肿瘤疗效,
小鼠B16 F10黑色素瘤模型。我们将测试中心假设,即PC 7A纳米颗粒疫苗
将与检查点抑制协同作用,以允许黑色素瘤的安全和有效的T细胞疗法。
具体目标有三:(1)将纳米疫苗平台扩展到多种黑色素瘤肽
(2)评价聚合物纳米疫苗在健康、免疫活性
(3)评价聚合物纳米疫苗的抗肿瘤功效及其与药物的协同作用。
检查点抑制上述目标的实现将为临床提供关键数据
用于黑色素瘤治疗的纳米疫苗的翻译。我们还将与其他
nanoalliance成员测试PC 7A NP在其他癌症适应症中的作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jinming Gao其他文献
Jinming Gao的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jinming Gao', 18)}}的其他基金
STING Activating Synthetic Nanovaccine for HPV-Induced Cancers
STING 激活合成纳米疫苗治疗 HPV 诱发的癌症
- 批准号:
9892979 - 财政年份:2018
- 资助金额:
$ 51.95万 - 项目类别:
STING Activating Synthetic Nanovaccine for HPV-Induced Cancers
STING 激活合成纳米疫苗治疗 HPV 诱发的癌症
- 批准号:
10371057 - 财政年份:2018
- 资助金额:
$ 51.95万 - 项目类别:
STING Activating Synthetic Nanovaccine for HPV-Induced Cancers
STING 激活合成纳米疫苗治疗 HPV 诱发的癌症
- 批准号:
10113555 - 财政年份:2018
- 资助金额:
$ 51.95万 - 项目类别:
STING-Activating Polymeric Nanovaccines for T Cell Therapy of Melanoma
用于黑色素瘤 T 细胞治疗的 STING 激活聚合物纳米疫苗
- 批准号:
9982225 - 财政年份:2017
- 资助金额:
$ 51.95万 - 项目类别:
STING-Activating Polymeric Nanovaccines for T Cell Therapy of Melanoma
用于黑色素瘤 T 细胞治疗的 STING 激活聚合物纳米疫苗
- 批准号:
9371064 - 财政年份:2017
- 资助金额:
$ 51.95万 - 项目类别:
STING-Activating Polymeric Nanovaccines for T Cell Therapy of Melanoma
用于黑色素瘤 T 细胞治疗的 STING 激活聚合物纳米疫苗
- 批准号:
10229423 - 财政年份:2017
- 资助金额:
$ 51.95万 - 项目类别:
Ultra-Responsive "ON/OFF" Fluorescent Nanoprobes for Cancer Molecular Imaging
用于癌症分子成像的超响应“开/关”荧光纳米探针
- 批准号:
8705515 - 财政年份:2011
- 资助金额:
$ 51.95万 - 项目类别:
Ultra-Responsive "ON/OFF" Fluorescent Nanoprobes for Cancer Molecular Imaging
用于癌症分子成像的超响应“开/关”荧光纳米探针
- 批准号:
8193961 - 财政年份:2011
- 资助金额:
$ 51.95万 - 项目类别:
Ultra-Responsive "ON/OFF" Fluorescent Nanoprobes for Cancer Molecular Imaging
用于癌症分子成像的超响应“开/关”荧光纳米探针
- 批准号:
8516037 - 财政年份:2011
- 资助金额:
$ 51.95万 - 项目类别:
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
- 批准号:
BB/Y006224/1 - 财政年份:2024
- 资助金额:
$ 51.95万 - 项目类别:
Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
- 批准号:
10083718 - 财政年份:2023
- 资助金额:
$ 51.95万 - 项目类别:
Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
- 批准号:
480030 - 财政年份:2023
- 资助金额:
$ 51.95万 - 项目类别:
Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
- 批准号:
MR/X009254/1 - 财政年份:2023
- 资助金额:
$ 51.95万 - 项目类别:
Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
- 批准号:
22KJ1758 - 财政年份:2023
- 资助金额:
$ 51.95万 - 项目类别:
Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
- 批准号:
BB/Y000927/1 - 财政年份:2023
- 资助金额:
$ 51.95万 - 项目类别:
Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
- 批准号:
10795212 - 财政年份:2023
- 资助金额:
$ 51.95万 - 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
- 批准号:
23K18249 - 财政年份:2023
- 资助金额:
$ 51.95万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
- 批准号:
10735075 - 财政年份:2023
- 资助金额:
$ 51.95万 - 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
- 批准号:
10645989 - 财政年份:2023
- 资助金额:
$ 51.95万 - 项目类别: